EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to investigate the steady-state pharmacokinetics of
efavirenz in older HIV-infected patients as compared to historical controls; to investigate
the relationship of drug exposure to neuropsychiatric side effects and neuropsychological
performance; and to explore the role of host polymorphisms in drug metabolism in the older
patient.